News

1

Jul, 2020

ODYSSEY (Penta 20) trial plays an important role in the FDA approval of dolutegravir for children – a big step towards timely access to optimal ART for children

Tags: ,

Data from the ongoing P1093 and ODYSSEY (PENTA20) studies have led to the successful approval of ViiV Healthcare’s submission to the U.S. Food and Drug Administration (FDA) of the adult formulation for children weighing ≥20kg and dolutegravir (DTG) dispersible tablets for children of 4 weeks of age and older.

READ MORE

19

Jun, 2020

What did Penta get up to in 2019?

 

COVID-19, the new infectious disease which has uprooted our lives, social relationships and work habits, has turned out to be an unmissable opportunity to rethink our collaborative research and strive to drive attention to those who we care most.

READ MORE

18

Jun, 2020

COVID-19: what’s important to us

 

COVID-19, the new infectious disease which has uprooted our lives, social relationships and work habits, has turned out to be an unmissable opportunity to rethink our collaborative research and strive to drive attention to those who we care most.

READ MORE